Twist Bioscience Corp (TWST) - Total Assets
Based on the latest financial reports, Twist Bioscience Corp (TWST) holds total assets worth $672.44 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Twist Bioscience Corp - Total Assets Trend (2016–2025)
This chart illustrates how Twist Bioscience Corp's total assets have evolved over time, based on quarterly financial data. Also see Twist Bioscience Corp market capitalisation for the company's overall valuation and market capitalisation.
Twist Bioscience Corp - Asset Composition Analysis
Current Asset Composition (September 2025)
Twist Bioscience Corp's total assets of $672.44 Million consist of 51.9% current assets and 48.1% non-current assets. Review Twist Bioscience Corp balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.5% |
| Accounts Receivable | $57.32 Million | 8.9% |
| Inventory | $28.31 Million | 4.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.43 Million | 2.1% |
| Goodwill | $82.19 Million | 12.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Twist Bioscience Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Twist Bioscience Corp (TWST) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Twist Bioscience Corp's current assets represent 51.9% of total assets in 2025, a decrease from 77.2% in 2016.
- Cash Position: Cash and equivalents constituted 28.5% of total assets in 2025, down from 37.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 12.8% of total assets.
Twist Bioscience Corp Competitors by Total Assets
Key competitors of Twist Bioscience Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Twist Bioscience Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.67 | 3.90 | 8.67 |
| Quick Ratio | 2.38 | 3.60 | 8.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $201.04 Million | $252.71 Million | $483.44 Million |
Twist Bioscience Corp - Advanced Valuation Insights
This section examines the relationship between Twist Bioscience Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.89 |
| Latest Market Cap to Assets Ratio | 12.87 |
| Asset Growth Rate (YoY) | 4.5% |
| Total Assets | $641.86 Million |
| Market Capitalization | $8.26 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Twist Bioscience Corp's assets at a significant premium (12.87x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Twist Bioscience Corp's assets grew by 4.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Twist Bioscience Corp (2016–2025)
The table below shows the annual total assets of Twist Bioscience Corp from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $641.86 Million | +4.48% |
| 2024-09-30 | $614.32 Million | -20.88% |
| 2023-09-30 | $776.40 Million | -19.24% |
| 2022-09-30 | $961.38 Million | +36.93% |
| 2021-09-30 | $702.10 Million | +76.02% |
| 2020-09-30 | $398.88 Million | +113.31% |
| 2019-09-30 | $186.99 Million | +61.49% |
| 2018-09-30 | $115.79 Million | +35.18% |
| 2017-09-30 | $85.66 Million | +12.02% |
| 2016-09-30 | $76.46 Million | -- |
About Twist Bioscience Corp
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo … Read more